Arjo — Earnings Release 2025

Jan 30, 2026

{0}------------------------------------------------

October-December 2025 in brief

• Net sales amounted to SEK 2,814 M (2,989). Net sales grew organically by 3.4%.
• The gross margin was 42.1% (44.7).
• Adjusted EBITDA amounted to SEK 526 M (653).
• Adjusted operating profit amounted to SEK 249 M (375).
• Profit after financial items amounted to SEK 104 M (245).
• Earnings per share before and after dilution amounted to SEK 0.26 (0.64).
• Cash flow from operations rose to SEK 600 M (479), corresponding to a cash conversion of 119.9% (82.3).
• Exceptional items amounted to SEK 68 M (88), most of which were related to activities to strengthen the Group's long-term profitability.
• A dividend per share of SEK 0.95 (0.95) is proposed, corresponding to approximately SEK 259 M.
• The new date for the Annual General Meeting will be April 22, 2026.

Outlook 2026

• Organic sales growth for 2026 is expected to be within the Group's target interval of 3–5%.

despite a somewhat weaker end than expected we are growing in line with our target, which remains unchanged again for 2026. Profitability did not perform at the level we would have liked, with headwinds from currencies, tariffs and mix effects. At the same time, the trend in cash flow was positive and we are just below the 80% cash conversion target for the full-year.

There is significant potential to further strengthen our market position, offering, and efficiency going forward. We are now launching the work to develop a new strategy for Arjo, together with our employees, and to ensure its successful execution."

ANDRÉAS ELGAARD PRESIDENT AND CEO

Financial summary

SEK M	Quarter 4 2025	Quarter 4 2024	Full-year 2025	Full-year 2024
Net sales	2,814	2,989	11,000	11,292
Gross profit	1,185	1,336	4,684	4,907
Gross margin, %	42.1	44.7	42.6	43.5
Adjusted EBITDA1)	526	653	1,922	2,086
Adjusted EBITDA margin, %1)	18.7	21.9	17.5	18.5
Adjusted EBITA1)	323	436	1,091	1,263
Adjusted EBITA margin, %1)	11.5	14.6	9.9	11.2
Operating profit (EBIT)	182	287	675	893
Adjusted operating profit (EBIT)1)	249	375	831	1,019
Profit after financial items	104	245	467	684
Net profit for the period	70	174	334	498
Number of shares, thousands	272,370	272,370	272,370	272,370
Earnings per share, SEK	0.26	0.64	1.23	1.83
Cash flow from operations	600	479	1,435	1,516
Cash conversion, %	119.9	82.3	79.3	76.7

^1. Before exceptional items. See Alternative performance measures on page 16 and definitions on page 19.

{1}------------------------------------------------

Continued stable demand but challenging profitability

Now three weeks into my role as the CEO of Arjo, I would like to begin by saying how proud I am to lead a company that truly makes a difference – for people with reduced mobility and for the healthcare professionals who do their utmost every single day. As populations age and the need for care continues to grow, I see many opportunities to further strengthen Arjo's position by leveraging our unique product portfolio and close customer relationships. I will return to this shortly, but first I would like to briefly reflect on the closing of 2025.

Stable demand

Demand for Arjo's products and solutions remains stable and we grew 3.4% organically in the quarter, which means that we also reach the lower part of our target interval for the full-year.

Performance in North America was stable with continued growth in the US, despite the delayed flu season and the temporary shutdown of the US federal government. Canada also grew in the quarter, despite strong comparative figures.

Global Sales delivered healthy growth in several European and emerging markets. At the same time, we saw a continued negative trend in the UK driven by a challenging market situation, and we are closely monitoring developments to ensure the right priorities going forward.

Despite a slightly weaker end to the year than expected, we are closing a year with solid global demand and a positive trend in key categories such as patient handling and service. It is evident that the new products launched during the year are appreciated among customers, which strengthens us going forward.

Weak gross margin development

Profitability in the fourth quarter did not perform at the level we would have liked. The gross margin declined to 42.1% (44.7), primarily impacted by negative currency effects and US tariffs, which together accounted for about one percentage point of the decline. In addition, we saw headwinds from both a product mix and geographical mix during the quarter, corresponding to an additional one percentage point. The remaining impact was driven by price pressure in DVT in the US and weaker margins in the US rental operations. Costs were also slightly higher than expected at the end of the quarter and, combined with the lower gross margin, this meant that adjusted operating profit declined to SEK 249 M (375).

Cash conversion in line with our target

The trend in cash flow was positive, mainly due to an improved performance in working capital, and we ended the year with a cash conversion of 120%. This means that we were in line with our target of 80% for the full-year, and shows that our initiatives are having an effect. It also means that we have room to together build on an even more robust platform for the future.

We are now setting the direction for the next step on Arjo's journey

Overall, we did not reach the level of performance we had expected in 2025. At the same time, Arjo has a solid foundation, and I am convinced that there is significant potential to create higher long-term value in our business. We are therefore now initiating the work to define a clear direction for Arjo and to identify concrete initiatives to support long-term profitable growth. During the spring, we will analyze our own capabilities, gather insights from customers, employees and experts, and establish a clear, actionable plan for the years ahead. Our ambition is to present the outcome of this work in the second half of 2026.

At the same, we will ensure a strong focus on our business and our customers, as well as internal efficiency. Demand is solid and our ambition is to continue to grow in line with our previous target of 3–5% also in 2026.

I would like to thank Niclas Sjöswärd for his efforts in 2025 and for a smooth handover. I would also like to thank all our employees for their dedication as well as our customers and shareholders for their trust. We have a solid foundation to stand on – and even greater opportunities ahead.

ANDRÉAS ELGAARD, PRESIDENT & CEO

{2}------------------------------------------------

Group performance

Net sales per segment

SEK M	Quarter 4 2025	Quarter 4 2024	Organic change	Full-year 2025	Full-year 2024	Organic change
Global Sales	1,665	1,726	3.6%	6,344	6,481	2.2%
North America	1,055	1,175	2.7%	4,269	4,415	5.6%
Diagnostics	100	93	10.4%	409	408	1.0%
Eliminations	–6	–4	—	–22	–12	—
Total	2,814	2,989	3.4%	11,000	11,292	3.4%

Net sales and results

Fourth quarter 2025

Net sales for the quarter amounted to SEK 2,814 M (2,989), corresponding to an organic increase of 3.4%.

Sales in North America increased organically by 2.7%. The US continued to perform positively, despite lower revenue from the rental operations following a late start to the influenza season and the temporary shutdown of the federal government for parts of the quarter. Demand remained high in patient handling and service in the US. Canada continued to report sales growth for the fourth quarter. However, after several quarters of strong growth and a very strong comparative quarter, growth was slightly lower in the fourth quarter.

Sales in Global Sales increased organically by 3.6%. The trend was positive in several European markets, such as France, Germany, the Netherlands and Italy. The trend was also favorable in several emerging markets, such as India, Hong Kong and Singapore. The UK continued to perform negatively during the quarter.

The gross margin fell to 42.1% (44.7) during the quarter. Negative currency effects and US tariffs had an adverse impact of a total of SEK 145 M, of which the costs of US tariffs accounted for approximately SEK 16 M. Mix effects also had a negative impact in the quarter, with higher sales in emerging markets and a higher share of sales of medical beds. Price pressure in DVT in the US continued, and the margin trend was also weaker in the US rental operations due to the late influenza season.

Operating expenses for the quarter amounted to SEK 928 M (981), corresponding to an organic increase of 1.9%.

Exceptional items amounted to SEK 68 M, most of which were related to measures to strengthen the Group's profitability in the long term. Approximately SEK 35 M related to an impairment of IT systems, where Arjo's current structure, featuring several different ERP systems in the Group's operations, will be replaced with a shared global ERP system. This action is part of an ongoing effort to reduce the Group's long-term IT costs. The transition to the shared ERP system is scheduled to be completed by the end of 2027 and is expected to lead to annual savings of approximately SEK 30 M from 2028. Approximately SEK 18 M related to restructuring activities in the UK, such as a change of premises and adapting the organization to the current market situation.

Adjusted EBITDA amounted to SEK 526 M (653) and the adjusted EBITDA margin was 18.7% (21.9).

Adjusted operating profit amounted to SEK 249 M (375). Currency effects and US tariffs had a negative impact of approximately SEK 87 M on adjusted operating profit.

Net financial items for the quarter amounted to SEK –77 M (–41). Positive currency effects in net financial items amounted to SEK 2 M (4). A revaluation of the holdings in Atlas Mobility, Veplas and Infonomy had a negative impact of SEK 35 M on net financial items.

Profit before tax amounted to SEK 104 M (245).

January-December 2025

Europe and China.

Net sales for the year amounted to SEK 11,000 M (11,292), corresponding to an organic increase of 3.4%. Demand for capital equipment was healthy during the year and service also performed well.

North America grew 5.6% organically during the year, with a positive performance in both the US and Canada. Demand was particularly high for capital goods, with a positive trend for patient handling equipment, as well as service.

Global Sales grew 2.2% organically with a healthy trend in markets such as Germany, Italy and the Netherlands. Growth was held back by a negative performance in the UK, which experienced a challenging market situation during the year. In the Rest of the World, New Zealand, India and the African markets performed particularly well.

The gross margin declined to 42.6% (43.5), mainly due to negative currency effects and US tariffs. Costs for US tariffs increased approximately SEK 37 M year-on-year. In addition, an unfavorable product mix, with a high sales of medical beds, negatively impacted the gross margin during the year. Continued work on price adjustments and cost efficiency, as well as enhanced productivity in the Group's factories, had a positive impact during the year.

Operating expenses for the year amounted to SEK 3,814 M (3,896). Exceptional costs amounted to SEK 155 M for the year and mainly related to changes in the Arjo Management Team, impairment of IT systems as part of reducing the Group's IT costs in the long term, and restructuring activities linked to changes in the sales organizations in

Adjusted EBITDA for the period amounted to SEK 1,922 M (2,086). The adjusted EBITDA margin was 17.5% (18.5).

Adjusted operating profit declined to SEK 831 M (1,019), mainly due to the lower gross margin. Profit before tax amounted to SEK 467 M (684).

Net financial items amounted to SEK –209 M (–209) for the period. Positive currency effects in net financial items amounted to SEK 10 M (17) for the period.

{3}------------------------------------------------

Currency effects

SEK M	Quarter 4 2025	Jan–Dec 2025
Translation effect (vs 2024)
Sales	–282	–668
Cost of goods sold	+179	+424
Gross profit	–103	–244
Operating expenses	+76	+182
Restructuring and other operating income/expenses	+3	+5
Total translation effect, EBIT	–23	–56
Transaction effect (vs 2024)
Cost of goods sold	–25	–66
Recognized remeasurement effects
Other operating income/expenses	–3	–44

Translation effects for the quarter amounted to SEK –23 M and transaction effects to SEK –25 M. In addition, the recognized revaluation effects of operating receivables and liabilities amounted to SEK –3 M for the quarter.

Cash flow and financial position

Cash flow from operations amounted to SEK 600 M (479) for the quarter and included a positive contribution of SEK 204 M (–55) from changes in working capital. The trend in working capital in the quarter was mainly the result of a decline in inventories. Accounts receivable performed better compared with the year-earlier quarter since a higher share of sales took place earlier in the quarter than in the comparative period. Cash conversion was 119.9% (82.3) for the quarter and 79.3% (76.7) for the full-year, which was in line with the Group's target of 80%.

Net investments for the quarter amounted to SEK 152 M (179), divided between tangible assets of SEK 79 M (102) and intangible assets of SEK 74 M (77). The investments in tangible assets include investments in the rental fleet of SEK 54 M (50).

The Group's cash and cash equivalents amounted to SEK 836 M (892) and interest-bearing net debt was SEK 4,255 M (4,191). Arjo has contracted unutilized credit facilities of SEK 5,319 M (4,827) available for refinancing outstanding commercial paper. The equity/assets ratio amounted to 49.8% (51.2). Net debt/adjusted EBITDA was 2.2 (2.0).

Research and development

Arjo's gross research and development costs for the quarter amounted to SEK 69 M (79), of which SEK 29 M (34) was charged to operating profit. The gross costs correspond to 2.5% (2.6) of consolidated net sales.

Outlook 2026

Organic sales growth for 2026 is expected to be within the Group's target interval of 3–5%.

2026 Annual General Meeting

Arjo's Annual General Meeting will be held on April 22, 2026 in Malmö, Sweden. Shareholders wishing to have a matter addressed at the AGM can submit their proposal to Arjo's Board Chairman by e-mail: agm@ arjo.com, or by mail: Arjo AB, Att: Bolagsstämmoärenden, Hans Michelsensgatan 10, SE–211 20 Malmö, Sweden. To ensure inclusion in the notice and thus in the Annual General Meeting's agenda, proposals must be received by the company by March 4, 2026.

Ahead of the 2026 Annual General Meeting, Arjo's Nomination Committee comprised Chairman Carl Bennet (Carl Bennet AB), Jannis Kitsakis (Fourth Swedish National Pension Fund), Anders Oscarsson (Svolder AB), as well as Board Chairman Johan Malmquist.

Dividend

Arjo's Board of Directors and CEO propose a dividend for 2025 of SEK 0.95 per share (0.95). The total dividend thus amounts to approximately SEK 259 M (259). The Board's proposed record date is April 24, 2026. Euroclear expects to distribute the dividend to shareholders on April 29, 2026.

Other events during the quarter New date for Annual General Meeting 2026

Arjo's Board of Directors has decided to bring forward the date of the Annual General Meeting 2026 to April 22, instead of the previously communicated date of April 29.

Second issue under MTN program completed

In November, Arjo completed a second issue of SEK 1 billion within the framework of its MTN program (Medium Term Note). The MTN program was established in May 2025, to further diversify the company's sources of funding as well as support strategic initiatives.

The bonds are issued with floating rate and a maturity of 2 years (SEK 250 M) and 4 years (SEK 750 M), and are traded at Nasdaq Stockholm.

More information about the MTN program is available on Arjo's website: https://www.arjo.com/int/about-us/investors/credit-market/

{4}------------------------------------------------

Other information

Risk management

Customers and healthcare reimbursement systems

A considerable share of Arjo's revenue is derived from sales of products to public sector entities. A political discussion taking place in certain countries concerns whether private healthcare providers should be able to offer publicly funded healthcare services. There is a risk that authorities in countries where Arjo operates will decide to limit or completely discontinue public funding of private healthcare, which could affect the establishment of new hospitals and other healthcare facilities and their purchasing of healthcare products, such as Arjo's emergency and longterm care products. Sales of the Group's products are also dependent on various reimbursement systems in each of Arjo's markets. In many of Arjo's markets (such as the US), it is often the patient's insurance company that – within the framework of the existing political reimbursement system – funds or subsidizes products for the patient's emergency or long-term care. Some of the success in sales of Arjo's products in these markets is dependent on whether Arjo's products have been approved for reimbursement under the various reimbursement systems. Since Arjo conducts operations in many different countries and markets, the above-named risks are limited for the Group as a whole. As part of Arjo's strategy, the Group is increasingly focusing on highlighting the clinical and financial benefits of the Group's products and solutions, something that further reduces the risks described above.

Research and development

Arjo's future growth is also dependent on the continued expansion of new product segments and new product types in existing product segments, which is dependent on the Group's ability to influence, predict, identify and respond to changing customer preferences and needs. Arjo invests in research and development in order to produce and launch new products, but there is no guarantee that any new products will achieve the same degree of success as in the past. Nor is there any certainty that Arjo will succeed in predicting or identifying trends in customer preferences and needs, or that Arjo will identify them earlier than its competitors. To maximize the return on research and development efforts, the Group has a highly structured selection and planning process to ensure that the Group prioritizes correctly when making decisions about potential projects. This process includes careful analyses of the market, technological progress, circularity, product life cycle, choice of production method and selection of subsuppliers. Development activities are conducted in a structured manner and the deliveries of every project undergo a number of fixed control points. Arjo is focused on products and solutions that will lead to more efficient care, in which more patients can be treated, which is expected to drive demand from end customers and therefore market growth. Product development that leads to a broader product range is a means for increasing organic growth in the market in which Arjo operates.

Product liability and damage claims

As a medical device supplier, Arjo, like other healthcare industry players, may sometimes be subject to claims related to product liability and other damage claims. Such claims could involve large financial amounts, result in significant legal expenses and negatively affect the company's reputation and customer relationships. Arjo limits the risk of product liability and other damage claims related to its products and their use through the company's extensive quality and safety activities. A comprehensive insurance program is in place to cover any liability risks (including product liability) to which the Group is exposed.

Protecting and managing the infringement of intellectual property rights

Arjo invests significant financial amounts in research and development, and is continuously developing new products and technological solutions. To secure revenue from these investments, new products and technologies must be protected from unlawful use by competitors. If possible and appropriate, Arjo protects its intellectual property rights by registering patents, design and trademarks. The Group is also dependent upon know-how and trade secrets that cannot be protected under intellectual property law.

Clear instructions are in place within the Group for how to prevent, investigate and manage potential infringements. In addition, procedures are in place to ensure efficient maintenance of the existing portfolio of rights.

Changes related to general economic and political conditions

Arjo operates in several parts of the world and, like other companies, is affected by general global economic, financial and political conditions. Demand for Arjo's medical devices and solutions is influenced by various factors, including general macroeconomic trends. Uncertainty about future economic prospects, including political concerns, could adversely affect customers' decisions to buy Arjo's products and solutions, which would adversely affect Arjo's operations, financial position and results. Furthermore, changes in the political situation in a region or country, or political decisions affecting an industry or country, could also have a material adverse impact on sales of Arjo's products. Since Arjo operates in a large number of geographical markets, this risk is limited for the Group as a whole.

Given the size of the US market and the uncertainty regarding tariffs on import goods, the outcome may have an impact on Arjo's operations. Therefore, the company is closely monitoring developments and continuously evaluating the situation and any potential action to mitigate the effects of any tariffs.

Arjo is also monitoring developments in other parts of the world, such as in the Middle East and Russia's full-scale invasion of Ukraine. Arjo has stopped all deliveries and production of equipment destined to Russia since 2022.

{5}------------------------------------------------

Risks in the value chain

Unforeseen and sudden events could cause disruptions to production or the supply chain, which could result in higher costs, delivery delays and non-delivery to Arjo's customers. This in turn could have a negative impact on the Group's earnings.

Sustainability-related risks

Arjo works actively to monitor and continuously evaluate sustainabilityrelated risks and their impact on the Group's operations and earnings. This takes place in the form of, for example, a regular double materiality assessment, monitoring targets and commitments and by auditing various units within the company, such as the security aspects of the Group's production facilities or random testing of regulatory compliance. The double materiality assessment is carried out as part of Enterprise Risk Management (ERM). The Group has established a governance structure that involves both the company management and the Board, and works continuously on improving the company's sustainability activities and minimizing associated risks.

Authorities and supervisory bodies

The healthcare market is highly regulated in all of the countries where Arjo operates. Arjo's product range is subject to legislation, including EU Directives and implementing acts regarding medical devices, and the US Food and Drug Administration's (FDA) regulations and related quality systems requirements, which also encompass comprehensive evaluation, quality assurance and product documentation.

Arjo devotes significant efforts and resources to implementing and applying guidelines to ensure regulatory compliance. Annual audits are performed by designated accreditation bodies to ensure compliance for continued CE marking of Arjo's products and international legal requirements, including the FDA, MDSAP, EU MDR and UK MDR.

All of the Group's production facilities are also certified according to ISO 13485 (Medical devices – quality management systems) and ISO 9001 (Quality management systems) from BSI.

Financial risk management

Through its operations, Arjo is exposed to a number of financial risks. Arjo's management of financial risks is regulated by a policy established by the Board. Ultimate responsibility for managing the Group's financial risks and developing methods and policies for mitigating these risks lies with Group management and Group Finance. The Group's financial risks comprise currency risk, interest-rate risk, credit and counterparty risk, and tax risk, of which currency is the most important risk.

Risk of cyber attacks

Arjo is dependent on IT and its surrounding infrastructure and thus is exposed to the risk of cyber attacks and other forms of intrusion and data security. A defined, governing process is in place to counteract potential risks in this area, and the company works actively on risk assessments of its IT infrastructure and sensitive data as well as testing of these areas. This includes defined mitigating processes and controls, known as IT General Control (ITGC) to protect the company. The internal control environment is evaluated every year both by the company's Chief Information Security Officer (CISO) and by the external auditors. A risk assessment under the EU Network and Information Security 2 (NIS2) Directive has been introduced and is regularly carried out as part of the Group's overall enterprise risk management (ERM). Sensitivity analyses and penetration and restoration tests are performed regularly during the year to ensure sufficient security levels for systems, processes and data. All employees undergo training in IT security and such training is part of the onboarding process for new employees.

Transactions with related parties

Transactions between Arjo and companies in Getinge Group are specified in Note 10.

Forward-looking information

This report contains forward-looking information based on the current expectations of Arjo's Management Team. Although management considers the expectations presented by such forward-looking information to be reasonable, there is no guarantee that these expectations will prove correct. Consequently, actual outcomes may vary considerably compared with what is stated in the forward-looking information, due to such factors as changed conditions regarding the economy, market and competition, changes in legal and regulatory requirements, as well as other policy measures and fluctuations in exchange rates.

This interim report is unaudited.

{6}------------------------------------------------

Assurance

The Board of Directors and CEO assure that the year-end report provides a true and fair review of the Parent Company and the Group's operations, position and earnings and describes the material risks and uncertainties faced by the Parent Company and the Group.

Malmö, January 30, 2026

Johan Malmquist Chairman of the Board Carl Bennet Vice Chairman of the Board Ulrika Dellby Board member Eva Elmstedt Board member

Dan Frohm Board member Ulf Grunander Board member Carola Lemne Board member Andréas Elgaard President & CEO

Madeléne Carlsson Board member Employee representative

Kajsa Haraldsson Board member Employee representative

{7}------------------------------------------------

Consolidated financial statements

CONDENSED CONSOLIDATED INCOME STATEMENT

SEK M	Note	Quarter 4 2025	Quarter 4 2024	Full-year 2025	Full-year 2024
Net sales	2	2,814	2,989	11,000	11,292
Cost of goods sold		-1,629	-1,653	-6,315	-6,386
Gross profit		1,185	1,336	4,684	4,907
Selling expenses		-542	-562	-2,211	-2,236
Administrative expenses		-358	-385	-1,463	-1,511
Research and development costs	4	-29	-34	-140	-150
Exceptional items	5	-68	-88	-155	-126
Other operating income and expenses		-7	20	-40	18
Income from participations in associated companies		-	0	-	-9
Operating profit (EBIT)	3	182	287	675	893
Net financial items		-77	-41	-209	-209
Profit after financial items		104	245	467	684
Taxes		-34	-72	-132	-187
Net Profit for the period		70	174	334	498
Attributable to:
Parent Company shareholders		70	174	334	498
Number of shares, thousands		272,370	272,370	272,370	272,370
Earnings per share, SEK1)		0.26	0.64	1.23	1.83

^1. Before and after dilution. For definition, see page 19.

{8}------------------------------------------------

CONDENSED CONSOLIDATED STATEMENT OF COMPREHENSIVE INCOME

SEK M	Quarter 4 2025	Quarter 4 2024	Full-year 2025	Full-year 2024
Net profit for the period	70	174	334	498
Other comprehensive income
Items that cannot be restated in profit
Actuarial gains/losses pertaining to defined-benefit pension plans	0	0	-2	20
Tax attributable to items that cannot be restated in profit	-2	-1	20	-8
Items that can later be restated in profit
Translation differences	-175	339	-1,131	585
Hedges of net investments	34	-27	101	-62
Cash-flow hedges	7	3	8	-2
Tax attributable to items that can be restated in profit	4	-13	48	-28
Other comprehensive income for the period, net after tax	-132	301	-957	504
Total comprehensive income for the period	-62	474	-622	1,002
Comprehensive income attributable to:
Parent Company shareholders	-62	474	-622	1,002

{9}------------------------------------------------

CONDENSED CONSOLIDATED BALANCE SHEET

SEK M	Note		Dec 31, 2025 Dec 31, 2024
Assets
Intangible assets		7,215	7,651
Tangible assets		1,486	1,695
Tangible lease assets		1,214	1,215
Financial assets	7	739	862
Inventories		1,177	1,388
Accounts receivables		1,617	1,798
Current financial receivables	7	27	29
Other current receivables		548	603
Cash and cash equivalents	7	836	892
Assets held for sale1)		119	143
Total assets		14,977	16,276
Shareholders' equity and liabilities
Shareholders' equity		7,457	8,338
Non-current financial liabilities	7	2,637	2,163
Non-current lease liabilities	7	858	851
Provisions for pensions, interest-bearing	7	34	36
Other provisions		285	348
Current financial liabilities	7	1,450	1,976
Current lease liabilities	7	408	428
Accounts payables		508	607
Other non-interest-bearing liabilities		1,339	1,530
Total shareholders' equity and liabilities		14,977	16,276

^1. From quarter 4 2024 Participations in the associated company BBI is reported as Assets held for sale.

CONDENSED CHANGES IN SHAREHOLDERS´ EQUITY FOR THE GROUP

SEK M	Share Capital	Reserves	Retained earnings	Total share holders´ equity1)
Opening balance at January 1, 2024	91	1,315	6,176	7,582
Net profit for the period	-	-	498	498
Other comprehensive income for the period, net after tax	-	492	12	504
Total comprehensive income for the period	-	492	509	1,002
Dividend	-	-	-245	-245
Closing balance at December 31, 2024	91	1,807	6,440	8,338
Opening balance at January 1, 2025	91	1,807	6,440	8,338
Net profit for the period	-	-	334	334
Other comprehensive income for the period, net after tax	-	-975	18	-957
Total comprehensive income for the period	-	-975	352	-622
Dividend	-	-	-259	-259
Closing balance at December 31, 2025	91	832	6,534	7,457

^1. Fully attributable to Parent Company shareholders.

{10}------------------------------------------------

CONDENSED CONSOLIDATED CASH-FLOW STATEMENT

Operating activities Operating profit (EBIT) 182 Add-back of amortization, depreciation and write-down 3 319 Other non-cash items -7 Expensed exceptional items1) 25 Paid exceptional items -25 Financial items -40 Taxes paid -57 Cash flow before changes to working capital 395 Changes in working capital Inventories 171 Current receivables Current liabilities 29 Cash flow from operations 600 Investing activities Acquired operations 11 -19 Net investments -152 Cash flow from investing activities -172 Financing activities Raising of loans 3,806 Repayment of financial liabilities -3,981 Repayment of lease liabilities -106 Change in pension assets/liabilities -1 Change in interest-bearing receivables Dividend Realized derivatives attributable to financing activities -1 Cash flow from financing activities -281 Cash flow for the period 147	Quarter 4 Quarter 4 2025 2024	Full-year 2025	Full-year 2024
	287	675	893
	296	1,136	1,084
	-26	-15	-41
	68	109	105
	-2	-105	-43
	-45	-177	-217
	-43	-208	-192
	534	1,415	1,589
	18	77	0
	4 -83	13	-98
	9	-70	25
	479	1,435	1,516
	-12	-27	-55
	-179	-678	-581
	-191	-705	-635
	5,036	19,736	26,835
	-5,091	-19,687	-27,170
	-121	-449	-431
	-1	-8	-6
	3 4	49	13
	- -	-259	-245
	47	-113	97
	-127	-730	-907
	161	0	-26
Cash and cash equivalents at the beginning of the period 705	718	892	923
Translation differences -17 Cash and cash equivalents at the end of the period 836	13 892	-56 836	-5 892

^1. Excluding write-down of non-current assets.

{11}------------------------------------------------

1 Accounting policies

The Group´s interim report has been prepared in accordance with IAS 34 Interim Financial Reporting and the applicable rules of Swedish Annual Accounts Act. The Parent Company has prepared the interim report in accordance with the Swedish Annual Accounts Act (1995:1554) and the Swedish Financial Reporting Board´s recommendation RFR 2, Accounting for Legal Entities.

The accounting policies applied in the preparation of this interim report apply to all periods and are consistent with the accounting policies presented in the 2024 Annual Report, published on www.arjo.com. No new or changed accounting standards that came into effect on January 1, 2025 had a material impact on Arjo. Arjo has decided

not to apply in advance new standards, amendments or interpretations that have been published but will not come into effect until the fiscal year beginning on or after January 1, 2026.

The totals in the tables and calculations do not always add up due to rounding differences. Each subtotal corresponds with its original source, which can lead to rounding differences in the totals.

During the fourth quarter 2024 the participation in the associated company BBI have been reclassified to assets held for sale. This means that the equity method is no longer applied and thus no share of profit is reported in the Income statement from the fourth quarter 2024.

2 Segment reporting

		Quarter 4 2025						Quarter 4 2024
SEK M	Global sales	North America	Diag nostic	Group functions	Elimi nations	Arjo Group	Global sales	North America	Diag nostic	Group functions	Elimi nations	Arjo Group
Product sales	842	638	90	-	-4	1,565	878	699	87	-	-3	1,661
Service incl. spare parts	395	169	10	-	-2	572	400	187	6	-	0	593
Revenue from contracts with customers	1,237	807	100	-	-6	2,137	1,278	886	93	-	-3	2,254
Rental	428	248	-	-	-	676	448	289	-	-	-1	735
Total net sales	1,665	1,055	100	-	-6	2,814	1,726	1,175	93	-	-4	2,989
Operating profit/loss	285	212	18	-333	-	182	340	280	22	-356	-	287
Net financial items						-77						-41
Profit after financial items						104						245
Taxes						-34						-72
Net profit for the period						70						174

				Full-year 2025 Full-year 2024
SEK M	Global sales	North America	Diag nostic	Group functions	Elimi nations	Arjo Group	Global sales	North America	Diag nostic	Group functions	Elimi nations	Arjo Group
Product sales	3,120	2,554	379	-	-20	6,033	3,269	2,621	385	-	-10	6,266
Service incl. spare parts	1,512	689	31	-	-2	2,229	1,478	711	23	-	0	2,212
Revenue from contracts with customers	4,632	3,243	409	-	-22	8,262	4,748	3,332	408	-	-10	8,478
Rental	1,711	1,026	-	-	-	2,737	1,733	1,082	-	-	-1	2,814
Total net sales	6,344	4,269	409	-	-22	11,000	6,481	4,415	408	-	-12	11,292
Operating profit/loss	914	953	63	-1,255	-	675	1,062	1,011	55	-1,235	-	893
Net financial items						-209						-209
Profit after financial items						467						684
Taxes						-132						-187
Net profit for the period						334						498

Arjo monitors its operations within the segments Global Sales, North America and Diagnostic (previously referred to as Other). Arjo has significant central Group functions in the areas of Supply Chain (product supply, inventory, and distribution), IT, Quality, and Research and Development. Only a certain portion of Supply Chain's expenses are allocated to each segment. The remaining expenses for the Group

functions are recognized as Group expenses. The division of segments and the method of measuring the segments' results areconducted in a similar way in this interim report as the 2024 Annual Report. Assets and liabilities are not divided by segment since no such amounts are regularly reported to the chief operating decision maker.

{12}------------------------------------------------

3 Depreciation/amortization and write-down

SEK M	Quarter 4 2025	Quarter 4 2024	Full-year 2025	Full-year 2024
Intangible assets	-109	-61	-296	-244
Of which, attributable to acquisitions	-17	-19	-70	-82
Tangible assets	-101	-123	-399	-412
Tangible lease assets	-108	-112	-441	-428
Total	-319	-296	-1,136	-1,084
Of which, write-down	-42	-17	-44	-17

Depreciation/amortization and write-downs by function, SEK M	Quarter 4 2025	Quarter 4 2024	Full-year 2025	Full-year 2024
Cost of goods sold	-179	-183	-722	-699
Selling expenses	-45	-44	-170	-166
Administrative expenses	-50	-49	-192	-192
Research and development costs	-2	-2	-7	-9
Other operating expenses	-	0	-	0
Exceptional items	-42	-17	-44	-17
Total	-319	-296	-1,136	-1,084
Of which, write-down	-42	-17	-44	-17

4 Capitalized development costs

SEK M	Quarter 4 2025	Quarter 4 2024	Full-year 2025	Full-year 2024
Research and development costs, gross	-69	-79	-303	-319
Capitalized development costs	41	45	163	169
Research and development costs, net	-29	-34	-140	-150

5 Exceptional items

SEK M	Quarter 4 2025	Quarter 4 2024	Full-year 2025	Full-year 2024
Acquisition expenses	-1	-4	-2	-4
Realisation loss BBI-assets	-	-54	-	-54
Impairment of ERP system	-35	-	-35	-
Restructuring and integration costs	-32	-31	-118	-68
Total	-68	-88	-155	-126

Exceptional items by function, SEK M	Quarter 4 2025	Quarter 4 2024	Full-year 2025	Full-year 2024
Cost of goods sold	-12	-8	-46	-21
Selling expenses	-10	-6	-20	-17
Administrative expenses	-46	-21	-86	-34
Research and development costs	0	-	-1	-
Other operating costs	0	-54	-2	-54
Total	-68	-88	-155	-126

The table above presents the function under which the items would have been recognized if they had not been classified as exceptional items.

{13}------------------------------------------------

6 Financial assets and liabilities measured at fair value

Dec 31, 2025, SEK M	Assets/liabilities measured at fair value through profit or loss	Derivatives used for hedging purposes	Total
Other current receivables, derivatives	4	-	4
Other financial assets	63	6	69
Total assets	67	6	73
Other non-interest-bearing liabilities, derivatives	3	-	3
Total liabilities	3	-	3

Dec 31, 2024, SEK M	Assets/liabilities measured at fair value through profit or loss	Derivatives used for hedging purposes	Total
Other current receivables, derivatives	17	-	17
Other financial assets	132	-	132
Total assets	149	-	149
Other non-interest-bearing liabilities, derivatives	11	2	13
Additional purchase consideration	15	-	15
Total liabilities	26	2	28

For a description of valuation techniques and inputs used in the valuation, please refer to Note 28 in the Annual Report for 2024. For other financial assets and liabilities in the Group, the reported values represent a reasonable approximation of their fair values.

7 Consolidated interest-bearing net debt

SEK M	Dec 31, 2025 Dec 31, 2024
Non-current financial liabilities	2,637	2,163
Non-current lease liabilities	858	851
Current financial liabilities	1,450	1,976
Current lease liabilities	408	428
Provisions for pensions	34	36
Interest-bearing liabilities	5,387	5,453
Less financial receivables	-82	-141
Less pension assets	-214	-229
Less cash and cash equivalents	-836	-892
Interest-bearing net debt	4,255	4,191

{14}------------------------------------------------

8 Key figures for the Group

SEK M	Quarter 4 2025	Quarter 4 2024	Full-year 2025	Full-year 2024
Sales measures
Net sales	2,814	2,989	11,000	11,292
Net sales growth, %	-5.9	3.8	-2.6	2.8
Organic growth in sales, %	3.4	3.1	3.4	3.1
Expense measures
Selling expenses as a % of net sales	19.3	18.8	20.1	19.8
Administrative expenses as a % of net sales	12.7	12.9	13.3	13.4
Research and development costs gross as a % of net sales	2.5	2.6	2.8	2.8
Earnings measures
EBITDA	500	582	1,811	1,977
EBITDA growth, %	-14.1	-1.1	-8.4	1.6
Adjusted EBITDA1)	526	653	1,922	2,086
EBITA	290	347	971	1,137
Adjusted EBITA1)	323	436	1,091	1,263
Operating profit (EBIT)	182	287	675	893
Adjusted operating profit (EBIT)1)	249	375	831	1,019
Earnings per share, SEK	0.26	0.64	1.23	1.83
Margin measures
Gross margin, %	42.1	44.7	42.6	43.5
EBITDA margin, %	17.8	19.5	16.5	17.5
Adjusted EBITDA margin, %1)	18.7	21.9	17.5	18.5
EBITA margin, %	10.3	11.6	8.8	10.1
Adjusted EBITA margin, %1)	11.5	14.6	9.9	11.2
Operating margin, %	6.5	9.6	6.1	7.9
Adjusted Operating margin, %1)	8.9	12.5	7.6	9.0
Cash flow and return measures
Return on shareholders' equity, %2)			4.2	6.3
Cash Conversion, %	119.9	82.3	79.3	76.7
Operating Capital			12,456	12,539
Return on operating capital, %2)			6.7	8.1
Capital Structure
Interest-bearing net debt			4,255	4,191
Interest-coverage ratio, multiple2)			4.0	4.2
Net debt/equity ratio, multiple			0.6	0.5
Net debt/adjusted EBITDA, multiple1, 2)			2.2	2.0
Equity/asset ratio, %			49.8	51.2
Equity per share, SEK			27.4	30.6
Other
Number of shares			272,369,573	272,369,573
Number of employees, average			6,942	6,932

^1. Before exceptional items. See Alternative performance measures on page 16 and definitions on page 19.

^2. Rolling 12 months.

{15}------------------------------------------------

ALTERNATIVE PERFORMANCE MEASURES

Alternative performance measures refer to financial measures used by the company´s management and investors to evaluate the Group´s earnings and financial position, and that cannot be directly read or derived from the financial statements. These financial measures are intended to facilitate analysis of the Group´s performance. The alternative performance measures should not be considered substitutes, but rather a supplement to, the financial statements prepared in

accordance with IFRS. The financial measures recognized in this report may differ from similar measures used by other companies. The alternative performance measures recognized below have not been calculated in accordance with IFRS but have been presented since Arjo believes that they are important in connection with investors´ assessments of the Company and the Company´s share.

Adjusted EBITDA/EBITA/EBIT SEK M	Quarter 4 2025	Quarter 4 2024	Full-year 2025	Full-year 2024
EBITDA	500	582	1,811	1,977
Depreciation and impairment of tangible assets	-210	-235	-840	-840
EBITA	290	347	971	1,137
Amortization and write-down of intangible assets	-109	-61	-296	-244
Operating profit (EBIT)	182	287	675	893
Exceptional items1)	68	88	155	126
Add-back of write-down of exceptional items	-42	-17	-44	-17
Adjusted EBITDA	526	653	1,922	2,086
Adjusted EBITA	323	436	1,091	1,263
Adjusted operating profit (EBIT)	249	375	831	1,019
Cash conversion	Quarter 4 2025	Quarter 4 2024	Full-year 2025	Full-year 2024
Cash flow from operations, SEK M	600	479	1,435	1,516
Operating profit (EBIT), SEK M	182	287	675	893
Add-back of amortization and write-down of intangible assets and tangible assets, SEK M	319	296	1,136	1,084
EBITDA, SEK M	500	582	1,811	1,977
Cash conversion, %	119.9	82.3	79.3	76.7
Net debt/equity ratio				Dec 31, 2025 Dec 31, 2024
Interest-bearing net debt, SEK M			4,255	4,191
Shareholder´s equity, SEK M			7,457	8,338
Net debt/equity ratio, multiple			0.6	0.5
Calculation of return on operating capital			Full-year 2025	Full-year 2024
Total assets opening balance, SEK M			16,276	15,444
Total assets closing balance, SEK M			14,977	16,276
Average total assets, SEK M			15,626	15,860
Average total assets, SEK M			15,626	15,860
Excluding average cash and cash equivalents, SEK M			-864	-908
Excluding average and other provisions, SEK M			-317	-327
Excluding average other non-interest-bearing liabilities, SEK M			-1,990	-2,087
Average operating capital, SEK M			12,456	12,539
Operating profit (EBIT), SEK M2)			675	893
Add-back of exceptional items, SEK M2)			155	126
EBIT after add-back of exceptional items, SEK M			831	1,019

Return on operation capital, % 6.7 8.1

^1. Refer to Note 5 Exceptional items.

^2. Rolling 12 months.

{16}------------------------------------------------

9 Financial data per quarter

SEK M	Quarter 1 2024	Quarter 2 2024	Quarter 3 2024	Quarter 4 2024	Quarter 1 2025	Quarter 2 2025	Quarter 3 2025	Quarter 4 2025
Net sales	2,759	2,810	2,734	2,989	2,863	2,678	2,646	2,814
Cost of goods sold	-1,560	-1,586	-1,587	-1,653	-1,613	-1,516	-1,558	-1,629
Gross profit	1,199	1,224	1,147	1,336	1,250	1,162	1,088	1,185
Operating expenses	-960	-985	-970	-981	-1,010	-951	-925	-928
Exceptional items	-29	-3	-5	-88	-40	-34	-13	-68
Other operating income, operating expenses and income from participations in associated companies	9	-7	-13	20	-32	-3	2	-7
Operating profit (EBIT)	219	229	158	287	168	174	152	182
Net financial items	-44	-65	-59	-41	-43	-48	-41	-77
Profit after financial items	175	164	100	245	125	126	111	104
Taxes	-44	-44	-27	-72	-34	-34	-30	-34
Net Profit for the period	132	120	73	174	91	92	81	70
Adjusted EBITDA1)	502	496	434	653	486	475	436	526
Adjusted EBITDA margin, %1)	18.2	17.7	15.9	21.9	17.0	17.7	16.5	18.7

^1. EBITDA before exceptional items. Refer to Note 5 Exceptional items, Alternative performance measures on page 16 and definitions on page 19.

10 Transactions with related parties

SEK M	Quarter 4 2025	Quarter 4 2024	Full-year 2025	Full-year 2024
Sales	5	5	23	22
Purchases of goods	-2	-2	-10	-9
Accounts receivable	0	2	2	3
Accounts payable	0	0	1	1

Carl Bennet AB is the parent company and has controlling influence over the Arjo Group. In addition to the customary dividend to Carl Bennet AB, Arjo has conducted transactions with companies within the Getinge Group, of which Carl Bennet AB also has controlling influence. Arjo uses Getinge as a distributor in certain markets. Transactions involving the delivery of products and services between the groups are carried out on commercial terms and at a market-based pricing. Transactions with the Getinge Group are specified in the table above. Apart from the above, no other material related party transactions have taken place.

11 Acquisitions

Acquisitions 2025

During the third quarter, Arjo acquired parts of the business of the Australian company Arden Maintenance Services Pty Ltd, which provides service of medical devices. The purchase price amounted to approximately SEK 5 M. The acquisition was made as an asset deal and is integrated into Arjo's existing operations in Australia. The acquired business has annual sales of approximately SEK 3 M.

During the fourth quarter, all shares were acquired in the three Dutch companies SlingCare B.V., SlingCare Products B.V., and Josh IP B.V., which specialize in patient handling solutions. The purchase price amounts to approximately SEK 19 M, and the annual sales amounts to approximately SEK 6 M. As the acquisitions are not considered material in relation to Arjo, no further disclosures are provided in this report.

Acquisitions 2024

During the third quarter, Arjo acquired all shares in the German company GerroMed Pflege- und Medizintechnik GmbH, which operates a rental business focused on pressure injury prevention. The annual sales amounts to approximately SEK 30 M.

During the fourth quarter, all shares in the French company Tech Med SAS, one of Arjo's distributors of diagnostic solutions, were acquired. The annual sales amounts to approximately SEK 25 M.

The purchase price for both acquisitions amounted to SEK 70 M in 2024, including additional purchase consideration. In 2025, the purchase price was adjusted and an additional SEK 2 M was paid.

{17}------------------------------------------------

Parent Company financial statements

CONDENSED PARENT COMPANY INCOME STATEMENT

SEK M	Quarter 4 2025	Quarter 4 2024	Full-year 2025	Full-year 2024
Net sales	320	329	320	329
Administrative expenses	-281	-294	-393	-431
Exceptional items1)	-	-3	-33	-3
Other operating income and expenses	-1	2	-1	1
Operating profit/loss (EBIT)	39	35	-107	-104
Income from participations in Group companies	175	137	471	1,029
Net financial items2)	-20	-9	-76	-90
Profit after financial items	194	163	288	835
Taxes	-45	-48	-4	-6
Net Profit for the period	149	115	284	830

^1. Exceptional items refers to restructuring costs of SEK -33 M (-), of which during the quarter SEK - M (-) and acquisition expenses of SEK 0 M (-3), of which during the quarter SEK - M (-3).

CONDENSED PARENT COMPANY BALANCE SHEET

SEK M		Dec 31, 2025 Dec 31, 2024
Assets
Intangible assets	384	339
Participations in Group companies	5,932	5,932
Other financial assets	62	109
Non-current financial receivables, Group companies	2,000	-
Other current receivables, Group companies	306	284
Current receivables	44	36
Cash and cash equivalents	0	0
Total assets	8,727	6,700
Shareholders' equity and liabilities
Shareholders' equity	4,583	4,558
Non-current financial liabilities	2,000	-
Provisions	7	2
Current financial liabilities	845	1,936
Current financial liabilities, Group companies	1,244	161
Other current liabilities, Group companies	14	3
Other non-interest-bearing liabilities	34	41
Total shareholders' equity and liabilities	8,727	6,700

The Parent Company´s commercial paper program has a framework amount of SEK 5,000 M (5,000). The total amount issued at the end of the period amounts to SEK 842 M (1,944). During the period, bonds of SEK 2 bn were issued under the MTN program with a term of two to five years, which are recognized as non-current financial liabilities. Intangible assets comprise software.

^2. Net financial items contain interest income, interest expenses, other financial expenses and exchange-rate gains and losses attributable to the translation of financial receivables and liabilities in foreign currencies measured at the closing day rate.

{18}------------------------------------------------

Definitions

FINANCIAL TERMS

Adjusted EBIT/Operating profit

Operating profit with add-back of exceptional items.

Adjusted EBITA

EBITA with add-back of exceptional items.

Adjusted EBITA margin

Adjusted EBITA in relation to net sales.

Adjusted EBITDA

EBITDA with add-back of exceptional items.

Adjusted EBITDA margin

Adjusted EBITDA in relation to net sales.

Cash conversion

Cash flow from operations in relation to EBITDA.

Earnings per share

Profit for the period attributable to Parent Company shareholders in relation to average number of shares. The following data was used to calculate earnings per share for the period:

Profit for the period attributable to Parent Company shareholders SEK 334 M Number of shares, thousands 272,370 Earnings per share SEK 1.23

EBIT

Operating profit.

EBITA

Operating profit before amortization and write-down of intangible assets.

EBITA margin

EBITA in relation to net sales.

EBITDA

Operating profit before amortization, depreciation and write-down.

EBITDA margin

EBITDA in relation to net sales.

Equity/assets ratio

Shareholders' equity in relation to total assets.

Exceptional items

Total of acquisition and restructuring costs as well as major non-recurring items.

Interest-coverage ratio

Profit after financial items plus interest expenses and add-back of exceptional items in relation to interest expenses. Calculated based on rolling twelvemonth data.

Net debt/adjusted EBITDA

Average net debt in relation to rolling 12 months' adjusted EBITDA.

Net debt/equity ratio

Interest-bearing net debt in relation to shareholders' equity.

Operating capital

Average total assets less cash and cash equivalents, other provisions, accounts payable and other non-interest-bearing liabilities.

Operating expenses

Selling expenses, administrative expenses and research and development costs.

Operating margin

Operating profit in relation to net sales.

Organic change

A financial change adjusted for currency fluctuations, acquisitions and divestments.

Return on operating capital

Rolling 12 months' operating profit with add-back of exceptional items in relation to operating capital.

Return on shareholders' equity

Rolling 12 months' profit after tax in relation to average shareholders' equity.

MEDICAL AND OTHER TERMS

Compression therapy

Treatment technique which means that one uses outer pressure with a certain frequency and for a certain period of time to treat and prevent venous leg ulcers.

DVT (deep vein thrombosis)

Formation of a blood clot in one of the body's deep veins, often in the leg.

Edema

Swelling due to accumulation of fluid in tissues.

Ergonomics

A science concerned with designing the job to fit the worker to prevent illness and accidents.

ESG

An abbreviation that stands for environmental, social and governance, which are the non-financial factors in corporate reporting.

EU Medical Device Regulation (MDR)

Regulations created by the EU to ensue better protection for the public health and patient safety by establishing modernized and more robust EU legislation. All medical device manufacturers and distributors must comply with these regulations.

Pressure injuries

Sores that occur when blood flow to the skin is reduced by external pressure. Most common in patients with reduced mobility.

Prevention

Preventive activity/treatment.

Sequential VTE prevention

A treatment that aims to enhance the circulation of blood in the deep veins of the legs, which helps reduce deep vein thrombosis (blood clot in the deep veins of the legs).

US Food and Drug Administration (FDA)

The US authority responsible for protecting the public health by carrying out regular inspections of, among other things, medical devices.

VTE (venous thromboembolism)

The abbreviation VTE standards for venous thromboembolism – a blood clot in the veins, similar to DVT (above).

{19}------------------------------------------------

TELECONFERENCE

Fund managers, analysts and the media are invited to a teleconference on January 30 at 1:00 p.m. CET.

A presentation will be held during the telephone conference. Watch the teleconference via the following link: https://arjo.events.inderes.com/q4-report–2025

Participants who wish to ask verbal questions at the teleconference must register using the link below. Once registered, participants will receive a telephone number and ID number to use to log in to the conference. Registration link:

https://events.inderes.com/arjo/q4-report–2025/dial-in

Alternatively, use the following link to download the presentation: https://www.arjo.com/int/about-us/investors/reports--presentations/2026/

A recording of the teleconference will be available for three years via the following link:

https://arjo.events.inderes.com/q4-report–2025

FINANCIAL INFORMATION

Updated information on, for example, the Arjo share and corporate governance is available on Arjo's website www.arjo.com. The Annual Report, year-end report and interim reports are published in Swedish and English and are available for download at www.arjo.com

The following financial statements will be published in 2026:

Week 14 2025 Annual Report April 22, 2026 2026 Annual General Meeting April 22, 2026 Interim Report January-March 2026 July 14, 2026 Interim Report January-June 2026 October, 22 2026 Interim Report January-September 2026

CONTACT

Maria Nilsson

Executive Vice President, Communication & Public Relations +46 734 244 515 maria.nilsson@arjo.com

Erik Roslund

Investor Relations & Corporate Communications +46 768 996 303 erik.roslund@arjo.com

This information is information that Arjo AB is obliged to make public pursuant to the EU Market Abuse Regulation. The information was submitted for publication, through the agency of the contact person set out above, on January 30, 2026 at 12:00 p.m. CET.

At Arjo, we believe that empowering movement within healthcare environments is essential to quality care. Our products and solutions for patient transfers, hygiene, disinfection, diagnostics, treating leg ulcers, prevention of pressure injuries and deep vein thrombosis, and our medical beds are all designed to promote mobility, safety and dignity in all care situations. With approximately 7,000 people worldwide and 65 years caring for patients and healthcare professionals, we are committed to driving healthier outcomes for people facing mobility challenges.

Arjo AB · Corp. Reg. No. 559092–8064 · Hans Michelsensgatan 10 · SE–211 20 Malmö · Sweden

www.arjo.com